Recent Press Releases:

CYTOCHROMA GRANTED FDA APPROVAL TO COMMENCE PHASE II CLINICAL TRIAL FOR NOVEL TOPICAL TREATMENT OF PSORIASIS

Markham, Ontario, Canada — February 20, 2006 — Cytochroma Inc. announces that it has received approval from the U.S. Food and Drug Administration to proceed with a Phase II clinical trial for CTA018, a novel vitamin D analog developed for the treatment of psoriasis. The trial, a multicenter, randomized, double-blind, parallel-group comparative study in subjects with chronic plaque psoriasis, will evaluate the efficacy of CTA018 when applied topically once daily over a maximum of 15% body surface area.

The anticipated enrolment for the trial is 140 subjects at 14 clinical sites in the United States. Subjects will be placed into one of four separate dosing groups comprised of three different concentrations of CTA018 and corresponding cream base (vehicle control). All subjects will receive once daily topical treatment for 12 consecutive weeks.

The primary efficacy endpoint of the trial will be the Physician Static Global Assessment. Local and systemic safety and patient perception of CTA018 cream will be evaluated in addition to several secondary endpoints including a Quality of Life assessment.

“We were very encouraged by the results of the previous two Phase I trials.”, stated James M. Rae, Chief Executive Officer of Cytochroma Inc., “We are optimistic that CTA018 will prove to be a valuable alternative to current therapies.”

About CTA018

CTA018 is a novel vitamin D analog with a dual mechanism of action. It is a strong activator of the vitamin D signaling pathway and also a potent inhibitor of CYP24 activity (the enzyme responsible for the breakdown of vitamin D). CTA018 was specifically designed by Prof. Gary H. Posner and is protected under patents and patent applications exclusively licensed to Cytochroma Inc. from the Johns Hopkins University.

About Psoriasis

Psoriasis is a common immune-mediated chronic skin disease often characterized by red, scaly plaques that itch, burn, sting, and bleed easily. It afflicts approximately 125 million people worldwide; more than 70% of patients have the mild to moderate form. Psoriasis is found in all age groups and often seriously compromises the quality of life of those affected. Current methods of treatment are either inconvenient, show poor remission rates, and/or have serious side effects. Cytochroma has recognized that there is a need for improved therapies.

About Cytochroma Inc.

Cytochroma Inc. is a specialty drug development company targeting hyperproliferative disorders, autoimmune diseases and chronic kidney disease. The company is currently focused on developing and commercializing innovative vitamin D analogs, significantly having a dual mechanism of action, which address major medical needs in the treatment of psoriasis, secondary hyperparathyroidism, autoimmune disorders and cancer. For more information, please visit www.cytochroma.com.

For information contact:

Sheldon Kawarsky, Ph.D.
Director, Business Development
Cytochroma Inc.
330 Cochrane Drive
Markham, Ontario L3R 8E4
CANADA
Phone: (905) 479-5306 ext. 337
Fax: (905) 479-1287
sheldon.kawarsky@cytochroma.com

< go back >